Gregory Renza
Stock Analyst at RBC Capital
(2.19)
# 2,729
Out of 4,876 analysts
206
Total ratings
33.68%
Success rate
-1.06%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $47.04 | -25.60% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $22.14 | +17.43% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $2.77 | +188.81% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $2.22 | +125.23% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $43.82 | -8.72% | 10 | May 14, 2025 | |
| ONC BeOne Medicines | Maintains: Outperform | $312 → $311 | $243.20 | +27.88% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $109.00 | +57.81% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $7.29 | +338.96% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $280.77 | +13.97% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $26.00 | +161.54% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.64 | +312.09% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $12.50 | -4.00% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $4.14 | +238.16% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $11.78 | +129.20% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $21.84 | +179.30% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $23.74 | -24.16% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $5.85 | +720.51% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $1.98 | +406.33% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $3.75 | +166.67% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $14.70 | +219.73% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $33.90 | +68.14% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $7.29 | -45.13% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $0.56 | +257.14% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $8.27 | +311.12% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $5.22 | +206.81% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $4.80 | +3,650.00% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.72 | +4,563.64% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $1.00 | +2,902.10% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $47.04
Upside: -25.60%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $22.14
Upside: +17.43%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $2.77
Upside: +188.81%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $2.22
Upside: +125.23%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $43.82
Upside: -8.72%
BeOne Medicines
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $243.20
Upside: +27.88%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $109.00
Upside: +57.81%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $7.29
Upside: +338.96%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $280.77
Upside: +13.97%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $26.00
Upside: +161.54%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.64
Upside: +312.09%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $12.50
Upside: -4.00%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $4.14
Upside: +238.16%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $11.78
Upside: +129.20%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $21.84
Upside: +179.30%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $23.74
Upside: -24.16%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $5.85
Upside: +720.51%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $1.98
Upside: +406.33%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $3.75
Upside: +166.67%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $14.70
Upside: +219.73%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $33.90
Upside: +68.14%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $7.29
Upside: -45.13%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.56
Upside: +257.14%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $8.27
Upside: +311.12%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $5.22
Upside: +206.81%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $4.80
Upside: +3,650.00%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.72
Upside: +4,563.64%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $1.00
Upside: +2,902.10%